| Autor: |
Papadaki MA; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece., Papadaki E; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece., Chatziavraam S; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece., Aggouraki D; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece., Michaelidou K; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece., Fotsitzoudis C; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece.; Department of Medical Oncology, University General Hospital of Heraklion, 71500 Heraklion, Greece., Vassilakopoulou M; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece., Mavroudis D; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece.; Department of Medical Oncology, University General Hospital of Heraklion, 71500 Heraklion, Greece., Agelaki S; Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, 70013 Crete, Greece.; Department of Medical Oncology, University General Hospital of Heraklion, 71500 Heraklion, Greece. |
| Abstrakt: |
The Fas/Fas ligand (FasL) system is a major apoptosis-regulating pathway with a key role in tumor immune surveillance and metastasis. The expression of Fas/FasL on mammary tumor tissues holds prognostic value for breast cancer (BC) patients. We herein assessed Fas/FasL expression on circulating tumor cells (CTCs) and matched peripheral blood mononuclear cells (PBMCs) from 98 patients with metastatic BC receiving first-line treatment. Fas+, FasL+, and Fas+/FasL+ CTCs were identified in 88.5%, 92.3%, and 84.6% of CTC-positive patients, respectively. In addition, Fas+/FasL+, Fas-/FasL+, and Fas-/FasL- PBMCs were identified in 70.3%, 24.2%, and 5.5% of patients, respectively. A reduced progression-free survival (PFS) was revealed among CTC-positive patients (median PFS: 9.5 versus 13.4 months; p = 0.004), and specifically among those harboring Fas+/FasL+ CTCs (median PFS: 9.5 vs. 13.4 months; p = 0.009). On the other hand, an increased overall survival (OS) was demonstrated among patients with Fas+/FasL+ PBMCs rather than those with Fas-/FasL+ and Fas-/FasL- PBMCs (median OS: 35.7 vs. 25.9 vs. 14.4 months, respectively; p = 0.008). These data provide for the first time evidence on Fas/FasL expression on CTCs and PBMCs with significant prognostic value for patients with metastatic BC, thus highlighting the role of the Fas/FasL system in the peripheral immune response and metastatic progression of BC. |
